Pasar al contenido principal

AGREGACION DE PROTEINAS: ESTRATEGIAS TERAPEUTICAS, DIAGNOSTICO Y APLICACIONES

BIO2016-78310-R

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos I+D+i Retos de Investigación
Año convocatoria 2016
Plan Estatal 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario UNIVERSIDAD AUTONOMA DE BARCELONA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 31
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Tolcapone, a potent aggregation inhibitor for the treatment of familial leptomeningeal amyloidosis

  • Garcia de Carvalho Pinheiro, Francisca|||0000-0003-3778-1528
  • Varejão, Nathalia|||0000-0002-6952-8896
  • Esperante, Sebastián|||0000-0002-5778-6871
  • Santos Suárez, Jaime|||0000-0001-9045-7765
  • Velázquez-Campoy, Adrián|||0000-0001-5702-4538
  • Reverter Cendrós, David|||0000-0002-5347-0992
  • Pallarès i Goitiz, Irantzu|||0000-0002-8205-2060
  • Ventura, Salvador|||0000-0002-9652-6351
Hereditary transthyretin amyloidosis (ATTR) is a disease characterized by the extracellular deposition of transthyretin (TTR) amyloid fibrils. Highly destabilizing TTR mutations cause leptomeningeal amyloidosis, a rare, but fatal, disorder in which TTR aggregates in the brain. The disease remains intractable, since liver transplantation, the reference therapy for systemic ATTR, does not stop mutant TTR production in the brain. In addition, despite current pharmacological strategies have shown to be effective against in vivo TTR aggregation by stabilizing the tetramer native structure and precluding its dissociation, they display low brain permeability. Recently, we have repurposed tolcapone as a molecule to treat systemic ATTR. Crystal structures and biophysical analysis converge to demonstrate that tolcapone binds with high affinity and specificity to three unstable leptomeningeal TTR variants, stabilizing them and, consequently, inhibiting their aggregation. Because tolcapone is an FDA-approved drug that crosses the blood-brain barrier, our results suggest that it can translate into a first disease-modifying therapy for leptomeningeal amyloidosis.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Discovering putative prion-like proteins in plasmodium falciparum: a computational and experimental analysis

  • Pallarès, Irantzu
  • de Groot, Natalia S.
  • Iglesias, Valentin
  • Sant'Anna, Ricardo
  • Biosca, Arnau
  • Fernàndez Busquets, Xavier
  • Ventura, Salvador
Prions are a singular subset of proteins able to switch between a soluble conformation and a self-perpetuating amyloid state. Traditionally associated with neurodegenerative diseases, increasing evidence indicates that organisms exploit prion-like mechanisms for beneficial purposes. The ability to transit between conformations is encoded in the so-called prion domains, long disordered regions usually enriched in glutamine/asparagine residues. Interestingly, Plasmodium falciparum, the parasite that causes the most virulent form of malaria, is exceptionally rich in proteins bearing long Q/N-rich sequence stretches, accounting for roughly 30% of the proteome. This biased composition suggests that these protein regions might correspond to prion-like domains (PrLDs) and potentially form amyloid assemblies. To investigate this possibility, we performed a stringent computational survey for Q/N-rich PrLDs on P. falciparum. Our data indicate that ∼10% of P. falciparum protein sequences have prionic signatures, and that this subproteome is enriched in regulatory proteins, such as transcription factors and RNA-binding proteins. Furthermore, we experimentally demonstrate for several of the identified PrLDs that, despite their disordered nature, they contain inner short sequences able to spontaneously self-assemble into amyloid-like structures. Although the ability of these sequences to nucleate the conformational conversion of the respective full-length proteins should still be demonstrated, our analysis suggests that, as previously described for other organisms, prion-like proteins might also play a functional role in P. falciparum., This work was funded by grants BIO2016-78310-R to SV and BIO2014-52872-R to XF-B (Ministerio de Economía y Competitividad, Spain), which included FEDER funds, and by ICREA, ICREA ACADEMIA 2015 to SV. ISGlobal and IBEC are members of the CERCA Program, Generalitat de Catalunya.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

In silico characterization of human prion-like proteins: beyond neurological diseases

  • Iglesias, Valentin
  • Paladin, Lisanna
  • Juan Blanco, Teresa, 1989-
  • Pallarès, Irantzu
  • Aloy, Patrick, 1972-
  • Tosatto, Silvio C.E.
  • Ventura, Salvador
Prion-like behavior has been in the spotlight since it was first associated with the onset of mammalian neurodegenerative diseases. However, a growing body of evidence suggests that this mechanism could be behind the regulation of processes such as transcription and translation in multiple species. Here, we perform a stringent computational survey to identify prion-like proteins in the human proteome. We detected 242 candidate polypeptides and computationally assessed their function, protein-protein interaction networks, tissular expression, and their link to disease. Human prion-like proteins constitute a subset of modular polypeptides broadly expressed across different cell types and tissues, significantly associated with disease, embedded in highly connected interaction networks, and involved in the flow of genetic information in the cell. Our analysis suggests that these proteins might play a relevant role not only in neurological disorders, but also in different types of cancer and viral infections., SV was supported by Ministerio de Economía y Competitividad (MINECO) (BIO2016-78310-R) and by ICREA, ICREA ACADEMIA 2015 to SV. PA was supported by MINECO (BIO2016-77038-R) and the European Research Council Consolidator grant, SysPharmAD (614944). TJ-B is a recipient of an FPI-SO fellowship. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

A pyrene-inhibitor fluorescent probe with large Stokes shift for the staining of Aβ1–42, α-synuclein, and amylin amyloid fibrils as well as amyloid-containing Staphylococcus aureus biofilms

  • Mahía Moros, Alejandro
  • Conde-Giménez, María
  • Salillas, Sandra
  • Pallarés, Irantzu
  • Galano-Frutos, Juan J.
  • Lasa, Íñigo
  • Ventura, Salvador
  • Díaz de Villegas, María D.
  • Gálvez, José A.
  • Sancho, Javier
Amyloid fibrils formed by a variety of peptides are biological markers of different human diseases, such as Alzheimer's disease, Parkinson's disease, and type II diabetes, and are structural constituents of bacterial biofilms. Novel fluorescent probes offering improved sensitivity or specificity toward that diversity of amyloid fibrils or providing alternative spectral windows are needed to improve the detection or the identification of amyloid structures. One potential source for such new probes is offered by molecules known to interact with fibrils, such as the inhibitors of amyloid aggregation found in drug discovery projects. Here we show the feasibility of the approach by designing, synthesizing, and testing several pyrene-based fluorescent derivatives of a previously discovered inhibitor of the aggregation of the Aβ1-42 peptide. All the derivatives tested retain the interaction with the amyloid architecture and allow its staining. The most soluble derivative, N-acetyl-2-(2-methyl-4-oxo-5,6,7,8-tetrahydro-4H-benzo[4,5]thieno[2,3-d][1,3]oxazin-7-yl)-N-(pyren-1-ylmethyl)acetamide (compound 1D), stains similarly well amyloid fibrils formed by Aβ1-42, α-synuclein, or amylin, provides a sensitivity only slightly lower than that of thioflavin T, displays a large Stokes shift, allows efficient excitation in the UV spectral region, and is not cytotoxic. Compound 1D can also stain amyloid fibrils formed by staphylococcal peptides present in biofilm matrices and can be used to distinguish, by direct staining, Staphylococcus aureus biofilms containing amyloid-forming phenol-soluble modulins from those lacking them., IL is supported by the Spanish Ministry of Economy and Competitiveness grant BIO2014-53530-R. SV is supported by grant BIO2016-783-78310-R and by ICREA (ICREA Academia 2015). MDD is supported by the Government of Aragon (GA E-102). JS is supported by grants BFU2016-78232-P (MINECO, Spain) and E45_17R (Gobierno de Aragón, Spain). JS and IL acknowledge financial support from grant CI-2017/001-3 (Campus Iberus, Spain). AM was a recipient of a predoctoral FPU fellowship from the Spanish Government., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Dual Binding Mode of Metallacarborane Produces aRobust Shieldon Proteins

  • Fuentes Sempere, Isabel
  • Pujols, Jordi
  • Viñas, Clara
  • Ventura, Salvador
  • Teixidor, Francesc
An inorganic sandwich molecule, Na[Co(C2B9H11)2], able to produce vesicles through self‐assembly and known to produce strong dihydrogen‐bond interactions with amine groups is capable of interacting with proteins. This dual non‐bonding ability of Na[Co(C2B9H11)2] is what makes this molecule unique: it can be firmly anchored to a protein surface and is capable of extending over it. To prove this, the widely available bovine serum albumin (BSA), which has many pendant amino groups in its structure, has been taken as the model protein. It has been found that around 100 molecules of Na[Co(C2B9H11)2] preserve the native structure of BSA, while endorsing it with a significantly increased stability with respect to chemical‐ and thermal‐induced denaturation due to efficient encapsulation. The advantages of this encapsulation technique are two‐fold; the first is its simplicity as it relies on the anchoring capacity of Na[Co(C2B9H11)2] to the surface of the protein through the amine‐containing residues and the second is its self‐assembling capacity allowing it to spread across the surface. The dense shield of protection offered by Na[Co(C2B9H11)2] has been demonstrated by the inhibition of BSA pseudo‐esterase activity, which indicates that the inorganic corset around BSA protects its reactive surface residues, thereby preventing their acetylation., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Tolcapone, a potent aggregation inhibitor for the treatment of familial leptomeningeal amyloidosis

  • Pinheiro, Francisco
  • Varejão, Nathalia
  • Esperante, Sebastian
  • Santos, J.
  • Velázquez-Campoy, Adrián
  • Reverter, David
  • Pallarés, Irantzu
  • Ventura, Salvador
15 pags., 9 figs., 3 tabs., Hereditary transthyretin amyloidosis (ATTR) is a disease characterized by the extracellular deposition of transthyretin (TTR) amyloid fibrils. Highly destabilizing TTR mutations cause leptomeningeal amyloidosis, a rare, but fatal, disorder in which TTR aggregates in the brain. The disease remains intractable, since liver transplantation, the reference therapy for systemic ATTR, does not stop mutant TTR production in the brain. In addition, despite current pharmacological strategies have shown to be effective against in vivo TTR aggregation by stabilizing the tetramer native structure and precluding its dissociation, they display low brain permeability. Recently, we have repurposed tolcapone as a molecule to treat systemic ATTR. Crystal structures and biophysical analysis converge to demonstrate that tolcapone binds with high affinity and specificity to three unstable leptomeningeal TTR variants, stabilizing them and, consequently, inhibiting their aggregation. Because tolcapone is an FDA-approved drug that crosses the blood-brain barrier, our results suggest that it can translate into a first disease-modifying therapy for leptomeningeal amyloidosis. DATABASES: PDB codes for A25T-TTR, V30G-TTR, and Y114C-TTR bound to tolcapone are 6TXV, 6TXW, and 6XTK, respectively., This work was funded by the Spanish Ministry of Economy and Competitiveness BIO2016-78310-R to SV and by ICREA, ICREA-Academia 2015, to SV
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

α-Helical peptidic scaffolds to target α-synuclein toxic species with nanomolar affinity

  • Santos, Jaime
  • Gracia, Pablo
  • Navarro, Susanna
  • Peña-Díaz, Samuel
  • Pujols, Jordi
  • Cremades, Nunilo
  • Pallarés, Irantzu
  • Ventura, Salvador
14 pags., 6 figs., α-Synuclein aggregation is a key driver of neurodegeneration in Parkinson’s disease and related syndromes. Accordingly, obtaining a molecule that targets α-synuclein toxic assemblies with high affinity is a long-pursued objective. Here, we exploit the biophysical properties of toxic oligomers and amyloid fibrils to identify a family of α-helical peptides that bind to these α-synuclein species with low nanomolar affinity, without interfering with the monomeric functional protein. This activity is translated into a high anti-aggregation potency and the ability to abrogate oligomer-induced cell damage. Using a structure-guided search we identify a human peptide expressed in the brain and the gastrointestinal tract with analogous binding, anti-aggregation, and detoxifying properties. The chemical entities we describe here may represent a therapeutic avenue for the synucleinopathies and are promising tools to assist diagnosis by discriminating between native and toxic α-synuclein species., This work was funded by the Spanish Ministry of Economy and Competitiveness (MINECO) BIO2016-78310-R and BIO2017-91475-EXP to S.V, by the Ministry of Science and Innovation (MICINN) PID2019-105017RB-I00 to S.V, by ICREA, ICREA-Academia 2015 to S.V. N.C. was supported by MINECO RYC-2012-12068, MINECO/FEDER, EU BFU2015-64119-P and MICIU/FEDER, EU PGC2018-096335-B-100. J.S. was supported by MICINN via a doctoral grant (FPU17/01157).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

An α-helical peptide-based plasmonic biosensor for highly specific detection of α-synuclein toxic oligomers

  • Giarola, Juliana Fátima
  • Santos, Jaime
  • Estévez, M. Carmen
  • Ventura, Salvador
  • Pallarès, Irantzu
  • Lechuga, Laura M.
[Background] α-Synuclein (αS) aggregation is the main neurological hallmark of a group of neurodegenerative disorders, collectively referred to as synucleinopathies, of which Parkinson's disease (PD) is the most prevalent. αS oligomers are elevated in the cerebrospinal fluid (CSF) of PD patients, standing as a biomarker for disease diagnosis. However, methods for early PD detection are still lacking. We have recently identified the amphipathic 22-residue peptide PSMα3 as a high-affinity binder of αS toxic oligomers. PSMα3 displayed excellent selectivity and reproducibility, binding to αS toxic oligomers with affinities in the low nanomolar range and without detectable cross-reactivity with functional monomeric αS., [Results] In this work, we leveraged these PSMα3 unique properties to design a plasmonic-based biosensor for the direct detection of toxic oligomers under label-free conditions., [Significance and novelty] We describe the integration of the peptide in a lab-on-a-chip plasmonic platform suitable for point-of-care measurements of αS toxic oligomers in CSF samples in real-time and at an affordable cost, providing an innovative biosensor for PD early diagnosis in the clinic., This work was funded by the Spanish Ministry of Economy and Competitiveness (MINECO) BIO2016-78310-R and BIO2017-91475-EXP to S.V, by the Ministry of Science and Innovation (MICINN) PID2019-105017RB-I00 to S.V, by ICREA, ICREA-Academia 2015 to S.V. J.S. was supported by MICINN via a doctoral grant (FPU17/01157). ICN2 is funded by the CERCA programme/Generalitat de Catalunya). The ICN2 is supported by Severo Ochoa Centres of Excellence programme, Grant CEX2021-001214-S, funded by MCIN/AEI/10.13039.501100011033. The NanoB2A group is a consolidated research group (Grup de Recerca) of the Generalitat de Catalunya and has support from the Departament de Recerca i Universitats de la Generalitat de Catalunya (expedient: 2021 SGR 00456)., With funding from the Spanish government through the "Severo Ochoa Centre of Excellence" accreditation (CEX2021-001214-S)., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

In silico characterization of human prion-like proteins: beyond neurological diseases

  • Iglesias, Valentin
  • Paladin, Lisanna
  • Juan Blanco, Teresa, 1989-
  • Pallarès, Irantzu
  • Aloy, Patrick, 1972-
  • Tosatto, Silvio C.E.
  • Ventura, Salvador
Prion-like behavior has been in the spotlight since it was first associated with the onset of mammalian neurodegenerative diseases. However, a growing body of evidence suggests that this mechanism could be behind the regulation of processes such as transcription and translation in multiple species. Here, we perform a stringent computational survey to identify prion-like proteins in the human proteome. We detected 242 candidate polypeptides and computationally assessed their function, protein-protein interaction networks, tissular expression, and their link to disease. Human prion-like proteins constitute a subset of modular polypeptides broadly expressed across different cell types and tissues, significantly associated with disease, embedded in highly connected interaction networks, and involved in the flow of genetic information in the cell. Our analysis suggests that these proteins might play a relevant role not only in neurological disorders, but also in different types of cancer and viral infections., SV was supported by Ministerio de Economía y Competitividad (MINECO) (BIO2016-78310-R) and by ICREA, ICREA ACADEMIA 2015 to SV. PA was supported by MINECO (BIO2016-77038-R) and the European Research Council Consolidator grant, SysPharmAD (614944). TJ-B is a recipient of an FPI-SO fellowship. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Discovering putative prion-like proteins in plasmodium falciparum: a computational and experimental analysis

  • Pallarès, Irantzu
  • de Groot, Natalia S.
  • Iglesias, Valentin
  • Sant'Anna, Ricardo
  • Biosca, Arnau
  • Fernàndez Busquets, Xavier
  • Ventura, Salvador
Prions are a singular subset of proteins able to switch between a soluble conformation and a self-perpetuating amyloid state. Traditionally associated with neurodegenerative diseases, increasing evidence indicates that organisms exploit prion-like mechanisms for beneficial purposes. The ability to transit between conformations is encoded in the so-called prion domains, long disordered regions usually enriched in glutamine/asparagine residues. Interestingly, Plasmodium falciparum, the parasite that causes the most virulent form of malaria, is exceptionally rich in proteins bearing long Q/N-rich sequence stretches, accounting for roughly 30% of the proteome. This biased composition suggests that these protein regions might correspond to prion-like domains (PrLDs) and potentially form amyloid assemblies. To investigate this possibility, we performed a stringent computational survey for Q/N-rich PrLDs on P. falciparum. Our data indicate that ∼10% of P. falciparum protein sequences have prionic signatures, and that this subproteome is enriched in regulatory proteins, such as transcription factors and RNA-binding proteins. Furthermore, we experimentally demonstrate for several of the identified PrLDs that, despite their disordered nature, they contain inner short sequences able to spontaneously self-assemble into amyloid-like structures. Although the ability of these sequences to nucleate the conformational conversion of the respective full-length proteins should still be demonstrated, our analysis suggests that, as previously described for other organisms, prion-like proteins might also play a functional role in P. falciparum., This work was funded by grants BIO2016-78310-R to SV and BIO2014-52872-R to XF-B (Ministerio de Economía y Competitividad, Spain), which included FEDER funds, and by ICREA, ICREA ACADEMIA 2015 to SV. ISGlobal and IBEC are members of the CERCA Program, Generalitat de Catalunya.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Aggrescan3D (A3D) 2.0, prediction and engineering of protein solubility

  • Kuriata, Aleksander
  • Iglesias, Valentin|||0000-0002-6133-0869
  • Pujols Pujol, Jordi|||0000-0001-9424-5866
  • Kurcinski, Mateusz
  • Kmiecik, Sebastian|||0000-0001-7623-0935
  • Ventura, Salvador|||0000-0002-9652-6351
Protein aggregation is a hallmark of a growing number of human disorders and constitutes a major bottleneck in the manufacturing of therapeutic proteins. Therefore, there is a strong need of in-silico methods that can anticipate the aggregative properties of protein variants linked to disease and assist the engineering of soluble protein-based drugs. A few years ago, we developed a method for structure-based prediction of aggregation properties that takes into account the dynamic fluctuations of proteins. The method has been made available as the Aggrescan3D (A3D) web server and applied in numerous studies of protein structure-aggregation relationship. Here, we present a major update of the A3D web server to version 2.0. The new features include: extension of dynamic calculations to significantly larger and multimeric proteins, simultaneous prediction of changes in protein solubility and stability upon mutation, rapid screening for functional protein variants with improved solubility, a REST-ful service to incorporate A3D calculations in automatic pipelines, and a new, enhanced web server interface. A3D 2.0 is freely available at: http://biocomp.chem.uw.edu.pl/A3D2/.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

In silico characterization of human prion-like proteins, beyond neurological diseases

  • Iglesias, Valentin|||0000-0002-6133-0869
  • Paladin, Lisanna
  • Juan Blanco, Teresa
  • Pallarès i Goitiz, Irantzu|||0000-0002-8205-2060
  • Aloy, Patrick|||0000-0002-3557-0236
  • Tosatto, Silvio|||0000-0003-4525-7793
  • Ventura, Salvador|||0000-0002-9652-6351
Prion-like behavior has been in the spotlight since it was first associated with the onset of mammalian neurodegenerative diseases. However, a growing body of evidence suggests that this mechanism could be behind the regulation of processes such as transcription and translation in multiple species. Here, we perform a stringent computational survey to identify prion-like proteins in the human proteome. We detected 242 candidate polypeptides and computationally assessed their function, protein-protein interaction networks, tissular expression, and their link to disease. Human prion-like proteins constitute a subset of modular polypeptides broadly expressed across different cell types and tissues, significantly associated with disease, embedded in highly connected interaction networks, and involved in the flow of genetic information in the cell. Our analysis suggests that these proteins might play a relevant role not only in neurological disorders, but also in different types of cancer and viral infections.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

ZPD-2, a small compound that inhibits α-synuclein amyloid aggregation and its seeded polymerization

  • Peña Díaz, Samuel|||0000-0002-2902-823X
  • Pujols Pujol, Jordi|||0000-0001-9424-5866
  • Conde Giménez, María|||0000-0003-4358-9110
  • Carija, Anita|||0000-0001-5972-7448
  • Dalfo, Esther|||0000-0003-4677-8515
  • García, Jesús
  • Navarro, Susanna|||0000-0001-8160-9536
  • Garcia de Carvalho Pinheiro, Francisca|||0000-0003-3778-1528
  • Santos Suárez, Jaime|||0000-0001-9045-7765
  • Salvatella, Xavier|||0000-0002-8371-4185
  • Sancho Sanz, Javier|||0000-0002-2879-9200
  • Ventura, Salvador|||0000-0002-9652-6351
α-Synuclein (α-Syn) forms toxic intracellular protein inclusions and transmissible amyloid structures in Parkinson's disease (PD). Preventing α-Syn self-assembly has become one of the most promising approaches in the search for disease-modifying treatments for this neurodegenerative disorder. Here, we describe the capacity of a small molecule (ZPD-2), identified after a high-throughput screening, to inhibit α-Syn aggregation. ZPD-2 inhibits the aggregation of wild-type α-Syn and the A30P and H50Q familial variants in vitro at substoichiometric compound:protein ratios. In addition, the molecule prevents the spreading of α-Syn seeds in protein misfolding cyclic amplification assays. ZPD-2 is active against different α-Syn strains and blocks their seeded polymerization. Treating with ZPD-2 two different PD Caenorhabditis elegans models that express α-Syn either in muscle or in dopaminergic (DA) neurons substantially reduces the number of α-Syn inclusions and decreases synuclein-induced DA neurons degeneration. Overall, ZPD-2 is a hit compound worth to be explored in order to develop lead molecules for therapeutic intervention in PD.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Discovering putative prion-like proteins in Plasmodium falciparum, a computational and experimental analysis

  • Pallarès i Goitiz, Irantzu|||0000-0002-8205-2060
  • Sánchez de Groot, Natalia|||0000-0002-0492-5532
  • Iglesias, Valentin|||0000-0002-6133-0869
  • Sant'Anna, Ricardo
  • Biosca, Arnau|||0000-0002-3047-8991
  • Fernández Busquets, Xavier|||0000-0002-4622-9631
  • Ventura, Salvador|||0000-0002-9652-6351
Prions are a singular subset of proteins able to switch between a soluble conformation and a self-perpetuating amyloid state. Traditionally associated with neurodegenerative diseases, increasing evidence indicates that organisms exploit prion-like mechanisms for beneficial purposes. The ability to transit between conformations is encoded in the so-called prion domains, long disordered regions usually enriched in glutamine/asparagine residues. Interestingly, Plasmodium falciparum, the parasite that causes the most virulent form of malaria, is exceptionally rich in proteins bearing long Q/N-rich sequence stretches, accounting for roughly 30% of the proteome. This biased composition suggests that these protein regions might correspond to prion-like domains (PrLDs) and potentially form amyloid assemblies. To investigate this possibility, we performed a stringent computational survey for Q/N-rich PrLDs on P. falciparum. Our data indicate that ~10% of P. falciparum protein sequences have prionic signatures, and that this subproteome is enriched in regulatory proteins, such as transcription factors and RNA-binding proteins. Furthermore, we experimentally demonstrate for several of the identified PrLDs that, despite their disordered nature, they contain inner short sequences able to spontaneously self-assemble into amyloid-like structures. Although the ability of these sequences to nucleate the conformational conversion of the respective full-length proteins should still be demonstrated, our analysis suggests that, as previously described for other organisms, prion-like proteins might also play a functional role in P. falciparum.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

DisProt, intrinsic protein disorder annotation in 2020

  • Hatos, András|||0000-0001-9224-9820
  • Hajdu-Soltész, Borbála
  • Monzon, Alexander M.
  • Palopoli, Nicolas
  • Álvarez, Lucía
  • Aykac-Fas, Burcu|||0000-0003-3842-731X
  • Bassot, Claudio|||0000-0001-7161-9028
  • Benítez, Guillermo I.
  • Bevilacqua, Martina|||0000-0001-7619-871X
  • Chasapi, Anastasia|||0000-0003-1986-5007
  • Chemes, Lucía Beatriz|||0000-0003-0192-9906
  • Davey, Norman E.|||0000-0001-6988-4850
  • Davidović, Radoslav|||0000-0002-6097-6203
  • Dunker, A. Keith
  • Elofsson, Arne|||0000-0002-7115-9751
  • Gobeill, Julien
  • Foutel, Nicolás S. G.
  • Sudha, Govindarajan
  • Guharoy, Mainak
  • Horvath, Tamas
  • Iglesias, Valentin|||0000-0002-6133-0869
  • Kajava, Andrey V.
  • Kovacs, Orsolya P.
  • Lamb, John
  • Lambrughi, Matteo|||0000-0002-0894-8627
  • Lazar, Tamas|||0000-0001-7496-6711
  • Leclercq, Jeremy Y.
  • Leonardi, Emanuela|||0000-0001-8486-8461
  • Macedo-Ribeiro, Sandra|||0000-0002-7698-1170
  • Macossay-Castillo, Mauricio
  • Maiani, Emiliano|||0000-0003-1432-5394
  • Manso, José A.
  • Marino-Buslje, Cristina|||0000-0002-6564-1920
  • Martínez-Pérez, Elisabeth
  • Mészáros, Bálint|||0000-0003-0919-4449
  • Mičetić, Ivan|||0000-0003-1691-8425
  • Minervini, Giovanni|||0000-0001-7013-5785
  • Murvai, Nikoletta
  • Necci, Marco|||0000-0001-9377-482X
  • Ouzounis, Christos|||0000-0002-0086-8657
  • Pajkos, Mátyás|||0000-0001-5791-9825
  • Paladin, Lisanna
  • Pancsa, Rita|||0000-0003-0849-9312
  • Papaleo, Elena|||0000-0002-7376-5894
  • Parisi, Gustavo|||0000-0001-7444-1624
  • Pasche, Emilie
  • Barbosa Pereira, Pedro José
  • Promponas, Vasilis J.|||0000-0003-3352-4831
  • Pujols Pujol, Jordi|||0000-0001-9424-5866
  • Quaglia, Federica|||0000-0002-0341-4888
  • Ruch, Patrick
  • Salvatore, Marco
  • Schad, Eva|||0000-0002-3006-2910
  • Szabo, Beata
  • Szaniszló, Tamás|||0000-0002-3130-9284
  • Tamana, Stella
  • Tantos, Agnes
  • Veljkovic, Nevena|||0000-0001-6562-5800
  • Ventura, Salvador|||0000-0002-9652-6351
  • Vranken, Wim|||0000-0001-7470-4324
  • Dosztányi, Zsuzsanna|||0000-0002-3624-5937
  • Tompa, Peter|||0000-0001-8042-9939
  • Tosatto, Silvio|||0000-0003-4525-7793
  • Piovesan, Damiano|||0000-0001-8210-2390
The Database of Protein Disorder (DisProt, URL: https://disprot.org) provides manually curated annotations of intrinsically disordered proteins from the literature. Here we report recent developments with DisProt (version 8), including the doubling of protein entries, a new disorder ontology, improvements of the annotation format and a completely new website. The website includes a redesigned graphical interface, a better search engine, a clearer API for programmatic access and a new annotation interface that integrates text mining technologies. The new entry format provides a greater flexibility, simplifies maintenance and allows the capture of more information from the literature. The new disorder ontology has been formalized and made interoperable by adopting the OWL format, as well as its structure and term definitions have been improved. The new annotation interface has made the curation process faster and more effective. We recently showed that new DisProt annotations can be effectively used to train and validate disorder predictors. We believe the growth of DisProt will accelerate, contributing to the improvement of function and disorder predictors and therefore to illuminate the 'dark' proteome.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

hnRNPDL phase separation is regulated by alternative splicing and disease-causing mutations accelerate its aggregation

  • Batlle Carreras, Cristina|||0000-0003-4903-831X
  • Yang, Peiguo
  • Coughlin, Maura
  • Messing, James
  • Pesarrodona Roches, Mireia|||0000-0001-9669-8471
  • Szulc, Elzbieta
  • Salvatella, Xavier|||0000-0002-8371-4185
  • Kim, Hong Joo
  • Taylor, J. Paul
  • Ventura, Salvador|||0000-0002-9652-6351
Prion-like proteins form multivalent assemblies and phase separate into membraneless organelles. Heterogeneous ribonucleoprotein D-like (hnRNPDL) is a RNA-processing prion-like protein with three alternative splicing (AS) isoforms, which lack none, one, or both of its two disordered domains. It has been suggested that AS might regulate the assembly properties of RNA-processing proteins by controlling the incorporation of multivalent disordered regions in the isoforms. This, in turn, would modulate their activity in the downstream splicing program. Here, we demonstrate that AS controls the phase separation of hnRNPDL, as well as the size and dynamics of its nuclear complexes, its nucleus-cytoplasm shuttling, and amyloidogenicity. Mutation of the highly conserved D378 in the disordered C-terminal prion-like domain of hnRNPDL causes limb-girdle muscular dystrophy 1G. We show that D378H/N disease mutations impact hnRNPDL assembly properties, accelerating aggregation and dramatically reducing the protein solubility in the muscle of Drosophila, suggesting a genetic loss-of-function mechanism for this muscular disorder.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Coiled-coil inspired functional inclusion bodies

  • Gil-Garcia, Marcos|||0000-0002-7457-7860
  • Navarro, Susanna|||0000-0001-8160-9536
  • Ventura, Salvador|||0000-0002-9652-6351
Recombinant protein expression in bacteria often leads to the formation of intracellular insoluble protein deposits, a major bottleneck for the production of soluble and active products. However, in recent years, these bacterial protein aggregates, commonly known as inclusion bodies (IBs), have been shown to be a source of stable and active protein for biotechnological and biomedical applications. The formation of these functional IBs is usually facilitated by the fusion of aggregation-prone peptides or proteins to the protein of interest, leading to the formation of amyloid-like nanostructures, where the functional protein is embedded. In order to offer an alternative to the classical amyloid-like IBs, here we develop functional IBs exploiting the coiled-coil fold. An in silico analysis of coiled-coil and aggregation propensities, net charge, and hydropathicity of different potential tags identified the natural homo-dimeric and anti-parallel coiled-coil ZapB bacterial protein as an optimal candidate to form assemblies in which the native state of the fused protein is preserved. The protein itself forms supramolecular fibrillar networks exhibiting only α-helix secondary structure. This non-amyloid self-assembly propensity allows generating innocuous IBs in which the recombinant protein of interest remains folded and functional, as demonstrated using two different fluorescent proteins. Here, we present a proof of concept for the use of a natural coiled-coil domain as a versatile tool for the production of functional IBs in bacteria. This α-helix-based strategy excludes any potential toxicity drawback that might arise from the amyloid nature of β-sheet-based IBs and renders highly active and homogeneous submicrometric particles.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Prion domains as a driving force for the assembly of functional nanomaterials

  • Wang, Weiqiang|||0000-0002-6962-8811
  • Ventura, Salvador|||0000-0002-9652-6351
Amyloids display a highly ordered fibrillar structure. Many of these assemblies appear associated with human disease. However, the controllable, stable, tunable, and robust nature of amyloid fibrils can be exploited to build up remarkable nanomaterials with a wide range of applications in biomedicine and biotechnology. Functional prions constitute a particular class of amyloids. These transmissible proteins exhibit a modular architecture, with a disordered prion domain responsible for the assembly and one or more globular domains that account for the activity. Importantly, the original globular protein can be replaced with any protein of interest, without compromising the fibrillation potential. These genetic fusions form fibrils in which the globular domain remains folded, rendering functional nanostructures. However, in some cases, steric hindrance restricts the activity of these fibrils. This limitation can be solved by dissecting prion domains into shorter sequences that keep their self-assembling properties while allowing better access to the active protein in the fibrillar state. In this review, we will discuss the properties of prion-like functional nanomaterials and the amazing applications of these biocompatible fibrillar arrangements.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

DispHred, a server to predict pH-dependent order-disorder transitions in intrinsically disordered proteins

  • Santos Suárez, Jaime|||0000-0001-9045-7765
  • Iglesias, Valentin|||0000-0002-6133-0869
  • Pintado-Grima, Carlos|||0000-0002-8544-959X
  • Santos-Suárez, Juan|||0000-0001-9360-2411
  • Ventura, Salvador|||0000-0002-9652-6351
The natively unfolded nature of intrinsically disordered proteins (IDPs) relies on several physicochemical principles, of which the balance between a low sequence hydrophobicity and a high net charge appears to be critical. Under this premise, it is well-known that disordered proteins populate a defined region of the charge-hydropathy (C-H) space and that a linear boundary condition is sufficient to distinguish between folded and disordered proteins, an approach widely applied for the prediction of protein disorder. Nevertheless, it is evident that the C-H relation of a protein is not unalterable but can be modulated by factors extrinsic to its sequence. Here, we applied a C-H-based analysis to develop a computational approach that evaluates sequence disorder as a function of pH, assuming that both protein net charge and hydrophobicity are dependent on pH solution. On that basis, we developed DispHred, the first pH-dependent predictor of protein disorder. Despite its simplicity, DispHred displays very high accuracy in identifying pH-induced order/disorder protein transitions. DispHred might be useful for diverse applications, from the analysis of conditionally disordered segments to the synthetic design of disorder tags for biotechnological applications. Importantly, since many disorder predictors use hydrophobicity as an input, the here developed framework can be implemented in other state-of-the-art algorithms.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Inhibition of α-synuclein aggregation and mature fibril disassembling with a minimalistic compound, ZPDm

  • Peña Díaz, Samuel|||0000-0002-2902-823X
  • Pujols Pujol, Jordi|||0000-0001-9424-5866
  • Garcia de Carvalho Pinheiro, Francisca|||0000-0003-3778-1528
  • Santos Suárez, Jaime|||0000-0001-9045-7765
  • Pallarès i Goitiz, Irantzu|||0000-0002-8205-2060
  • Navarro, Susanna|||0000-0001-8160-9536
  • Conde Giménez, María|||0000-0003-4358-9110
  • García, Jesús
  • Salvatella, Xavier|||0000-0002-8371-4185
  • Dalfo, Esther|||0000-0003-4677-8515
  • Sancho Sanz, Javier|||0000-0002-2879-9200
  • Ventura, Salvador|||0000-0002-9652-6351
Synucleinopathies are a group of disorders characterized by the accumulation of α-Synuclein amyloid inclusions in the brain. Preventing α-Synuclein aggregation is challenging because of the disordered nature of the protein and the stochastic nature of fibrillogenesis, but, at the same time, it is a promising approach for therapeutic intervention in these pathologies. A high-throughput screening initiative allowed us to discover ZPDm, the smallest active molecule in a library of more than 14.000 compounds. Although the ZPDm structure is highly related to that of the previously described ZPD-2 aggregation inhibitor, we show here that their mechanisms of action are entirely different. ZPDm inhibits the aggregation of wild-type, A30P, and H50Q α-Synuclein variants in vitro and interferes with α-Synuclein seeded aggregation in protein misfolding cyclic amplification assays. However, ZPDm distinctive feature is its strong potency to dismantle preformed α-Synuclein amyloid fibrils. Studies in a Caenorhabditis elegans model of Parkinson's Disease, prove that these in vitro properties are translated into a significant reduction in the accumulation of α-Synuclein inclusions in ZPDm treated animals. Together with previous data, the present work illustrates how different chemical groups on top of a common molecular scaffold can result in divergent but complementary anti-amyloid activities.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

MIRRAGGE - Minimum Information Required for Reproducible AGGregation Experiments

  • Martins, Pedro M.
  • Navarro, Susanna|||0000-0001-8160-9536
  • Silva, Alexandra
  • Pinto, Maria F.
  • Sárkány, Zsuzsa
  • Figueiredo, Francisco
  • Barbosa Pereira, Pedro José
  • Garcia de Carvalho Pinheiro, Francisca|||0000-0003-3778-1528
  • Bednarikova, Zuzana
  • Burdukiewicz, Michał|||0000-0001-8926-582X
  • Galzitskaya, Oxxana Valerianovna
  • Gazova, Zuzana
  • Gomes, Cláudio M.
  • Pastore, Annalisa|||0000-0002-3047-654X
  • Serpell, Louise C.
  • Skrabana, Rostislav
  • Smirnovas, Vytautas
  • Ziaunys, Mantas
  • Otzen, Daniel E.|||0000-0002-2918-8989
  • Ventura, Salvador|||0000-0002-9652-6351
  • Macedo-Ribeiro, Sandra|||0000-0002-7698-1170
Reports on phase separation and amyloid formation for multiple proteins and aggregation-prone peptides are recurrently used to explore the molecular mechanisms associated with several human diseases. The information conveyed by these reports can be used directly in translational investigation, e.g., for the design of better drug screening strategies, or be compiled in databases for benchmarking novel aggregation-predicting algorithms. Given that minute protocol variations determine different outcomes of protein aggregation assays, there is a strong urge for standardized descriptions of the different types of aggregates and the detailed methods used in their production. In an attempt to address this need, we assembled the Minimum Information Required for Reproducible Aggregation Experiments (MIRRAGGE) guidelines, considering first-principles and the established literature on protein self-assembly and aggregation. This consensus information aims to cover the major and subtle determinants of experimental reproducibility while avoiding excessive technical details that are of limited practical interest for non-specialized users. The MIRRAGGE table (template available in Supplementary Information) is useful as a guide for the design of new studies and as a checklist during submission of experimental reports for publication. Full disclosure of relevant information also enables other researchers to reproduce results correctly and facilitates systematic data deposition into curated databases.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Atomistic fibrillar architectures of polar prion-inspired heptapeptides

  • Peccati, Francesca|||0000-0002-7813-8216
  • Díaz-Caballero, Marta|||0000-0001-9032-9819
  • Navarro, Susanna|||0000-0001-8160-9536
  • Rodríguez-Santiago, Luis|||0000-0003-4983-4228
  • Ventura, Salvador|||0000-0002-9652-6351
  • Sodupe, Mariona|||0000-0003-0276-0524
This article provides the computational prediction of the atomistic architectures resulting from self-assembly of the polar heptapeptide sequences NYNYNYN, SYSYSYS and GYGYGYG. Using a combination of molecular dynamics and a newly developed tool for non-covalent interaction analysis, we uncover the properties of a new class of bionanomaterials, including hydrogen-bonded polar zippers, and the relationship between peptide composition, fibril geometry and weak interaction networks. Our results, corroborated by experimental observations, provide the basis for the rational design of prion-inspired nanomaterials.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

MED15 prion-like domain forms a coiled-coil responsible for its amyloid conversion and propagation

  • Batlle Carreras, Cristina|||0000-0003-4903-831X
  • Calvo, Isabel|||0000-0003-4107-296X
  • Iglesias, Valentin|||0000-0002-6133-0869
  • J. Lynch, Cian
  • Gil-Garcia, Marcos|||0000-0002-7457-7860
  • Serrano, Manuel|||0000-0001-7177-9312
  • Ventura, Salvador|||0000-0002-9652-6351
A disordered to β-sheet transition was thought to drive the functional switch of Q/N-rich prions, similar to pathogenic amyloids. However, recent evidence indicates a critical role for coiled-coil (CC) regions within yeast prion domains in amyloid formation. We show that many human prion-like domains (PrLDs) contain CC regions that overlap with polyQ tracts. Most of the proteins bearing these domains are transcriptional coactivators, including the Mediator complex subunit 15 (MED15) involved in bridging enhancers and promoters. We demonstrate that the human MED15-PrLD forms homodimers in solution sustained by CC interactions and that it is this CC fold that mediates the transition towards a β-sheet amyloid state, its chemical or genetic disruption abolishing aggregation. As in functional yeast prions, a GFP globular domain adjacent to MED15-PrLD retains its structural integrity in the amyloid state. Expression of MED15-PrLD in human cells promotes the formation of cytoplasmic and perinuclear inclusions, kidnapping endogenous full-length MED15 to these aggregates in a prion-like manner. The prion-like properties of MED15 are conserved, suggesting novel mechanisms for the function and malfunction of this transcription coactivator.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Cryptic amyloidogenic regions in intrinsically disordered proteins, Function and disease association

  • Santos Suárez, Jaime|||0000-0001-9045-7765
  • Pallarès i Goitiz, Irantzu|||0000-0002-8205-2060
  • Iglesias, Valentin|||0000-0002-6133-0869
  • Ventura, Salvador|||0000-0002-9652-6351
The amyloid conformation is considered a fundamental state of proteins and the propensity to populate it a generic property of polypeptides. Multiple proteome-wide analyses addressed the presence of amyloidogenic regions in proteins, nurturing our understanding of their nature and biological implications. However, these analyses focused on highly aggregation-prone and hydrophobic stretches that are only marginally found in intrinsically disordered regions (IDRs). Here, we explore the prevalence of cryptic amyloidogenic regions (CARs) of polar nature in IDRs. CARs are widespread in IDRs and associated with IDPs function, with particular involvement in protein-protein interactions, but their presence is also connected to a risk of malfunction. By exploring this function/malfunction dichotomy, we speculate that ancestral CARs might have evolved into functional interacting regions playing a significant role in protein evolution at the origins of life.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Functionalized Prion-Inspired Amyloids for Biosensor Applications

  • Díaz-Caballero, Marta|||0000-0001-9032-9819
  • Navarro, Susanna|||0000-0001-8160-9536
  • Ventura, Salvador|||0000-0002-9652-6351
Protein amyloid nanofibers provide a biocompatible platform for the development of functional nanomaterials. However, the functionalities generated up to date are still limited. Typical building blocks correspond to aggregation-prone proteins and peptides, which must be modified by complex and expensive reactions post-assembly. There is high interest in researching alternative strategies to tailor amyloid-based nanostructures' functionality on demand. In the present study, the biotin-streptavidin system was exploited for this purpose. Prion-inspired heptapeptides (Ac-NYNYNYN-NH, Ac-QYQYQYQ-NH, and Ac-SYSYSYS-NH) were doped with biotin-conjugated counterparts and assembled into amyloid-like fibers under mild conditions. The scaffolds' versatile functionalization was demonstrated by decorating them with different streptavidin conjugates, including gold nanoparticles, quantum dots, and enzymes. In particular, they were functionalized with peroxidase or phosphatase activities using streptavidin conjugated with horseradish peroxidase and alkaline phosphatase, respectively. Modification of amyloid-like nanostructures has generally been restricted to the addition of a single protein moiety. We functionalized the fibrils simultaneously with glucose oxidase and horseradish peroxidase, coupling these activities to build up a nanostructured glucose biosensor. Overall, we present a simple, modular, and multivalent approach for developing amyloid-based nanomaterials functionalized with any desired combination of chemical and biological moieties.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

α-Helical peptidic scaffolds to target α-synuclein toxic species with nanomolar affinity

  • Santos Suárez, Jaime|||0000-0001-9045-7765
  • Gracia González, Pablo
  • Navarro, Susanna|||0000-0001-8160-9536
  • Peña Díaz, Samuel|||0000-0002-2902-823X
  • Pujols Pujol, Jordi|||0000-0001-9424-5866
  • Cremades, Nunilo|||0000-0002-9138-6687
  • Pallarès i Goitiz, Irantzu|||0000-0002-8205-2060
  • Ventura, Salvador|||0000-0002-9652-6351
α-Synuclein aggregation is a key driver of neurodegeneration in Parkinson's disease and related syndromes. Accordingly, obtaining a molecule that targets α-synuclein toxic assemblies with high affinity is a long-pursued objective. Here, we exploit the biophysical properties of toxic oligomers and amyloid fibrils to identify a family of α-helical peptides that bind to these α-synuclein species with low nanomolar affinity, without interfering with the monomeric functional protein. This activity is translated into a high anti-aggregation potency and the ability to abrogate oligomer-induced cell damage. Using a structure-guided search we identify a human peptide expressed in the brain and the gastrointestinal tract with analogous binding, anti-aggregation, and detoxifying properties. The chemical entities we describe here may represent a therapeutic avenue for the synucleinopathies and are promising tools to assist diagnosis by discriminating between native and toxic α-synuclein species. α-Synuclein (αS) aggregation is a driver of several neurodegenerative disorders. Here, the authors identify a class of peptides that bind toxic αS oligomers and amyloid fibrils but not monomeric functional protein, and prevent further αS aggregation and associated cell damage.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Dual Antibody-Conjugated Amyloid Nanorods to Promote Selective Cell-Cell Interactions

  • Wang, Weiqiang|||0000-0002-6962-8811
  • Gil-Garcia, Marcos|||0000-0002-7457-7860
  • Ventura, Salvador|||0000-0002-9652-6351
Grafting biomolecules on nanostructures' surfaces is an increasingly used strategy to target pathogenic cells, with both diagnostic and therapeutic applications. However, nanomaterials monofunctionalized by conjugating a single type of ligand find limited uses in pathologies/therapies that require two or more targets/receptors to be targeted and/or activated with a single molecular entity simultaneously. Therefore, multivalent nanomaterials for dual- or multitargeting are attracting significant interest. This study provides a proof of concept of such nanostructures. We have recently developed a modular methodology that allows obtaining amyloid-based materials decorated with active globular domains. Here, this approach is exploited to generate functional amyloid fibrils displaying antibody capture moieties. A high antibody binding affinity and capacity for the resulting nanofibrils, whose size can be manipulated to obtain homogeneous nanorods with high biocompatibility, are demonstrated. These nanorods are then used for specific antibody-mediated targeting of different cell types. Simultaneous conjugation of these nanorods with different antibodies allows obtaining a mimic of a bispecific antibody that redirects T lymphocytes to tumoral cells, holding high potential for immunotherapy. Overall, the work illustrates a modular and straightforward strategy to obtain preparative quantities of multivalent antibody-functionalized nanomaterials with multitargeting properties without the need for covalent modification.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Development of a highly potent transthyretin amyloidogenesis inhibitor, design, synthesis, and evaluation

  • Garcia de Carvalho Pinheiro, Francisca|||0000-0003-3778-1528
  • Pallarès i Goitiz, Irantzu|||0000-0002-8205-2060
  • Peccati, Francesca|||0000-0002-7813-8216
  • Sánchez-Morales, Adrià|||0000-0002-8692-0988
  • Varejão, Nathalia|||0000-0002-6952-8896
  • Bezerra, Filipa|||0000-0002-1675-2317
  • Ortega-Alarcon, David|||0000-0003-1885-4365
  • González, Danilo|||0000-0002-2316-2016
  • Osorio, Marcelo
  • Navarro, Susanna|||0000-0001-8160-9536
  • Velázquez-Campoy, Adrián|||0000-0001-5702-4538
  • Almeida, Maria Rosário|||0000-0001-9289-3835
  • Reverter Cendrós, David|||0000-0002-5347-0992
  • Busqué, Félix|||0000-0001-7566-4264
  • Alibés, Ramon|||0000-0002-7997-2691
  • Sodupe, Mariona|||0000-0003-0276-0524
  • Ventura, Salvador|||0000-0002-9652-6351
Transthyretin amyloidosis (ATTR) is a group of fatal diseases described by the misfolding and amyloid deposition of transthyretin (TTR). Discovering small molecules that bind and stabilize the TTR tetramer, preventing its dissociation and subsequent aggregation, is a therapeutic strategy for these pathologies. Departing from the crystal structure of TTR in complex with tolcapone, a potent binder in clinical trials for ATTR, we combined rational design and molecular dynamics (MD) simulations to generate a series of novel halogenated kinetic stabilizers. Among them, M-23 displays one of the highest affinities for TTR described so far. The TTR/ M-23 crystal structure confirmed the formation of unprecedented protein-ligand contacts, as predicted by MD simulations, leading to an enhanced tetramer stability both in vitro and in whole serum. We demonstrate that MD-assisted design of TTR ligands constitutes a new avenue for discovering molecules that, like M-23, hold the potential to become highly potent drugs to treat ATTR.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Coiled-Coil Based Inclusion Bodies and Their Potential Applications

  • Gil-Garcia, Marcos|||0000-0002-7457-7860
  • Ventura, Salvador|||0000-0002-9652-6351
The production of recombinant proteins using microbial cell factories is frequently associated with the formation of inclusion bodies (IBs). These proteinaceous entities can be sometimes a reservoir of stable and active protein, might display good biocompatibility, and are produced efficiently and cost-effectively. Thus, these submicrometric particles are increasingly exploited as functional biomaterials for biotechnological and biomedical purposes. The fusion of aggregation-prone sequences to the target protein is a successful strategy to sequester soluble recombinant polypeptides into IBs. Traditionally, the use of these IB-tags results in the formation of amyloid-like scaffolds where the protein of interest is trapped. This amyloid conformation might compromise the protein's activity and be potentially cytotoxic. One promising alternative to overcome these limitations exploits the coiled-coil fold, composed of two or more α-helices and widely used by nature to create supramolecular assemblies. In this review, we summarize the state-of-the-art of functional IBs technology, focusing on the coiled-coil-assembly strategy, describing its advantages and applications, delving into future developments and necessary improvements in the field.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

pH-responsive self-assembly of amyloid fibrils for dual hydrolase-oxidase reactions

  • Díaz-Caballero, Marta|||0000-0001-9032-9819
  • Navarro, Susanna|||0000-0001-8160-9536
  • Nuez-Martínez, Miquel
  • Peccati, Francesca|||0000-0002-7813-8216
  • Rodríguez-Santiago, Luis|||0000-0003-4983-4228
  • Sodupe, Mariona|||0000-0003-0276-0524
  • Teixidor, Francesc|||0000-0002-3010-2417
  • Ventura, Salvador|||0000-0002-9652-6351
There is an increasing interest in synthetic systems that can execute bioinspired chemical reactions without requiring the complex structures that characterize enzymes in their components. The hierarchical self-assembly of peptides provides a means to create catalytic microenvironments. Ideally, as it occurs in enzymes, the catalytic activity of peptide nanostructures should be reversibly regulated. In a typical enzyme mimetic design, the peptide's self-assembling and catalytic activities are segregated into different regions of the sequence. Here, we aimed to design minimal peptides in which the self-assembly and function were all encoded in the same amino acids. Moreover, we wanted to endow the resulting one-component nanomaterial with divergent, chemically unrelated, catalytic activities, a property not observed in natural enzymes. We show that short peptides consisting only of histidine and tyrosine residues, arranged in a binary pattern, form biocompatible amyloid-like fibrils and hydrogels combining hydrolytic and electrocatalytic activities. The nanofibers' mesoscopic properties are controlled by pH, the transition between assembled active β-sheet fibrils, and disassembled inactive random coil species occurring in a physiologically relevant pH range. The structure of one of such amyloid-like fibrils, as derived from molecular dynamic simulations, provides insights on how they attain this combination of structural and catalytic properties.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

An α-helical peptide-based plasmonic biosensor for highly specific detection of α-synuclein toxic oligomers

  • Giarola, Juliana Fatima|||0000-0002-2121-0328
  • Santos Suárez, Jaime|||0000-0001-9045-7765
  • Estévez, M. Carmen|||0000-0003-3694-7186
  • Ventura, Salvador|||0000-0002-9652-6351
  • Pallarès i Goitiz, Irantzu|||0000-0002-8205-2060
  • Lechuga, Laura M.|||0000-0001-5187-5358
Background: α-Synuclein (αS) aggregation is the main neurological hallmark of a group of neurodegenerative disorders, collectively referred to as synucleinopathies, of which Parkinson's disease (PD) is the most prevalent. αS oligomers are elevated in the cerebrospinal fluid (CSF) of PD patients, standing as a biomarker for disease diagnosis. However, methods for early PD detection are still lacking. We have recently identified the amphipathic 22-residue peptide PSMα3 as a high-affinity binder of αS toxic oligomers. PSMα3 displayed excellent selectivity and reproducibility, binding to αS toxic oligomers with affinities in the low nanomolar range and without detectable cross-reactivity with functional monomeric αS. Results: In this work, we leveraged these PSMα3 unique properties to design a plasmonic-based biosensor for the direct detection of toxic oligomers under label-free conditions. Significance and novelty: We describe the integration of the peptide in a lab-on-a-chip plasmonic platform suitable for point-of-care measurements of αS toxic oligomers in CSF samples in real-time and at an affordable cost, providing an innovative biosensor for PD early diagnosis in the clinic.